Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet

Inclusion Criteria: * Male and female subjects with absence of significant diseases or clinically significant abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening. * Age of 18 - 55 years * Preferably non-smokers or smoke less than 10 cigarettes per day * Able to participate, communicate well with the investigators and willing to provide written informed consent to participate in the study. * BMI 18 - 25 kg/m2 * Vital signs (after 10 minutes rest) were within the following ranges: * SBP 100 - 120 mmHg * DBP 60 - 80 mmHg * Pulse rate 60 - 90 bpm Exclusion Criteria: * Personal/family history of allergy or hypersensitivity or contraindication to metformin hydrochloride or other biguanides and allied drug. * Pregnant or lactating women and women of childbearing potential without adequate contraception * Any major illnesses in the past 90 days or clinically significant ongoing chronic medical illnesses * Clinically significant illness within 4 weeks prior to the administration of study medication * Presence of any clinically significant abnormal values during screening * Positive Hepatitis B surface antigen (HBsAg), anti-HCV, or anti-HIV * Clinically significant haematology abnormalities * Clinically significant electrocardiogram (ECG) abnormalities * Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug * History of drug (cocaine, amphetamines, opiates, cannabis) or alcohol abuse within 12 months prior to screening for this study * Participation in any clinical trial within the past 90 days * History of any bleeding or coagulative disorders * History or presence of asthma bronchial or related bronchospastic conditions * History of seizures, epilepsy or any kind of neurological disorders * History of difficulty with donating blood or difficulty in vein puncture of left or right arm * A donation or loss of 500 mL (or more) of blood within 3 months before this study's first dosing day * Intake of any prescription or non-prescription drugs, food supplements or herbal medicines within 14 days of this study's first dosing day * Any food allergy, intolerance, restriction or special diet that in the opinion of the Research Physician, could contraindicate the subject's participation in this study * Any reason in the opinion of the Research Physician, would prevent the subject from participating in the study